1 2 3 4	Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
5 6 7 8 9 10	Panke Qu ^{1,2,#} , John P. Evans ^{1,2,3,#} , Chaitanya Kurhade ⁴ , Cong Zeng ^{1,2} , Yi-Min Zheng ^{1,2} , Kai Xu ^{1,2} , Pei-Yong Shi ⁴ , Xuping Xie ⁴ , Shan-Lu Liu ^{1,2,5,6,*}
12 13	¹ Center for Retrovirus Research, The Ohio State University, Columbus, OH 43210, USA
14	² Department of Veterinary Biosciences, The Ohio State University, Columbus, OH 43210, USA
15	³ Molecular, Cellular, and Developmental Biology Program, The Ohio State University,
16	Columbus, OH 43210, USA
17	⁴ Department of Biochemistry and Molecular Biology, University of Texas Medical Branch,
18	Galveston, TX 77555, USA
19	⁵ Viruses and Emerging Pathogens Program, Infectious Diseases Institute, The Ohio State
20	University, Columbus, OH 43210, USA
21	⁶ Department of Microbial Infection and Immunity, The Ohio State University, Columbus, OH
22	43210, USA
23	
24 25 27 28 29 30 31 32 33 34 35 36 37 38 39 40	*Authors contributed equally to this work *Corresponding Author: Liu.6244@osu.edu

41

42 Summary

43 The rapid spread and strong immune evasion of the SARS-CoV-2 Omicron subvariants 44 has raised serious concerns for the global COVID-19 pandemic. These new variants exhibit 45 reduced fusogenicity and increased endosomal entry pathway utilization compared to the 46 ancestral D614G variant, the underlying mechanisms of which remain elusive. Here we show that 47 the C-terminal S1 mutations of the BA.1.1 subvariant, H655Y and T547K, critically govern the low 48 fusogenicity of Omicron. Notably, H655Y also dictates the enhanced endosome entry pathway 49 utilization. Mechanistically, T547K and H655Y likely stabilize the spike trimer conformation, as 50 shown by increased molecular interactions in structural modeling as well as reduced S1 shedding. 51 Importantly, the H655Y mutation also determines the low fusogenicity and high dependence on 52 the endosomal entry pathway of other Omicron subvariants, including BA.2, BA.2.12.1, BA.4/5 53 and BA.2.75. These results uncover mechanisms governing Omicron subvariant entry and 54 provide insights into altered Omicron tissue tropism and pathogenesis.

- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63

64 Introduction

65 The emergence and rapid spread of the Omicron subvariants of SARS-CoV-2 around the world has caused serious concern about vaccine efficacy because of the large numbers of 66 67 mutations present in this lineage, with more than 30 substitutions in the Spike (S) proteins (Viana 68 et al., 2022). Indeed, many recent studies have shown that Omicron is resistant to neutralization 69 by antibodies induced by two-dose mRNA vaccination that is greatly restored by booster 70 vaccination (Carreno et al., 2022; Evans et al., 2022; Liu et al., 2022a; Perez-Then et al., 2022; 71 Planas et al., 2022; Xia et al., 2022; Yu et al., 2022). Consequently, Omicron led to a global surge 72 of COVID-19 cases. BA.1.1 and BA.1 were responsible for the initial Omicron wave, but were 73 replaced by the BA.2 subvariant, which was more transmissible and caused reinfection in patients 74 who previously were infected by BA.1 (Marc Stegger et al., 2022). Remarkably, derivatives of 75 BA.2, including BA.2.12.1 which subsequently became predominant in the US, and the BA.4 and 76 BA.5 subvariants bearing identical S proteins (referred to as BA.4/5 hereafter), which are currently 77 dominant in the world, are driving a new surge in cases as both have stronger immune escape 78 ability, especially the BA.4/5 variants (Cao et al., 2022; Hachmann et al., 2022; Qu et al., 2022a; 79 Wang et al., 2022). Despite the gradually improved virus transmissibility observed in these 80 subvariants, they appear to cause milder disease compared to Delta and other previous variants 81 (Diamond et al., 2021; Halfmann et al., 2022; McMahan et al., 2022). The mechanism underlying 82 the reduced pathogenicity of Omicron is currently unclear but has been under intense 83 investigation.

The SARS-CoV-2 S protein is a typical class I viral fusion protein that utilizes the cognate receptor angiotensin-converting enzyme 2 (ACE2) for binding and cellular entry (Hoffmann et al., 2020; Zhou et al., 2020). It has a furin cleavage site at the S1/S2 junction of S, which facilitates SARS-CoV-2 entry at the plasma membrane, viral replication in human lung epithelial cells, as well as transmission in animals (Mykytyn et al., 2021; Peacock et al., 2021). As SARS-CoV-2 evolves, its S has gained a large number of mutations and possibly undergone recombination, 90 resulting in the emergence of the initial D614G variant and several major variants of concern 91 (VOCs) such as Alpha, Beta, Gamma, Delta, and Omicron, some of which directly or indirectly 92 increase S cleavage to enhance fusogenicity (Escalera et al., 2022; Liu et al., 2022b; Saito et al., 93 2022). Intriguingly, results from many groups including ours have shown that the Omicron 94 subvariants exhibit substantially impaired cell-cell fusion capacity and tend to use the endosomal 95 entry pathway mediated by cathepsin L/B (Cat L/B), rather than the plasma membrane entry 96 pathway mediated by transmembrane protease serine 2 (TMPRSS2) which is preferred by other 97 previous variants (Du et al., 2022: Meng et al., 2022: Qu et al., 2022b).

98 Currently, the underlying molecular mechanism by which Omicron subvariants use 99 endosomal entry more efficiently than plasma membrane entry is unclear. Herein, we provide 100 evidence that some key mutations in S1 and/or the S1/S2 junction region of BA.1.1 S, such as 101 T547K and H655Y, especially the latter, dictate its intrinsically low fusogenicity and endosomal 102 entry. Mechanically, we find that T547K and H655Y restrict BA.1.1 S-mediated cell-cell fusion 103 possibly through stabilizing the S trimer conformation. Remarkably, H655Y, but not T547K which 104 is only carried by BA.1.1 and BA.1 of Omicron subvariants (Qu et al., 2022a), governs the entry 105 preference and fusion capability of all predominant Omicron subvariants. Together, our results 106 reveal that mutations in S1 around the furin cleavage site of Omicron S critically modulate the 107 unique biology of Omicron entry and are potentially associated with pathogenesis.

108

109 Results

110 Critical amino acid residues dictating the differential entry patterns of Omicron subvariant BA.1.1

111 in HEK293T-ACE2 and Calu-3 cells

Previous studies have shown that SARS-CoV-2 entry is cell-type dependent, depending on the efficiency of furin cleavage of the virus S protein and also the levels of TMPRSS2 expression on the plasma membrane of target cells (Bestle et al., 2020; Peacock *et al.*, 2021). In low TMPRSS2-expressing 293T-ACE2 and Vero cells, the endosomal entry pathway is 116 predominant; however, in Calu-3 and other cells expressing high levels of TMPRRS2, SARS-117 CoV-2 primarily uses the plasma membrane for entry (Hoffmann et al., 2020). We hypothesized 118 that mutations at the C-terminus of S1, or near the furin cleavage site of Omicron S, potentially 119 govern its endosomal entry. To test this hypothesis, we created reversion mutations specific to 120 residues T547K, H655Y, N679K, and P681H of the Omicron subvariant BA.1.1 (Fig. 1a), and 121 examined their impact on the entry of BA.1.1 into HEK293T-ACE2, HEK293T-ACE2-TMPRSS2 122 and Calu-3 cells using our previously reported HIV lentiviral pseudotyping system (Zeng et al., 123 2020). In parallel, the entry in these cell types was tested for the corresponding forward mutations. 124 i.e., T547K, H655Y, N679K, and P681H made in the backbone of the ancestral D614G construct 125 (Fig. 1a). We found that, compared with parental BA.1.1, the reversion mutation Y655H exhibited 126 a profound reduction of entry efficiency in HEK293T-ACE2 (Fig. 1b), and in HEK93T-ACE2-127 TMPRSS2 cells, albeit to a lesser extent (Fig. 1c), yet apparently enhanced entry in Calu-3 cells 128 (Fig. 1d), suggesting that H655Y is the most critical change in BA.1.1 S that distinguishes its entry 129 in these different cell types. Consistent with this, we observed that the forward mutation H655Y 130 exhibited reduced entry efficiency in Calu-3 cells, but increased entry in 293T-ACE2 and 293T-131 ACE-TMPRRS2 cells (Figs. 1e-f). While similar results were also observed for the BA.1.1 K547T 132 mutation, the impact on entry was not as dramatic as that of H655Y (**Figs. 1b-g**). Surprisingly, 133 two other mutations of BA.1.1, N679K and P681H, which are in close proximity to the furin 134 cleavage site, did not seem to obviously affect viral entry in these cell types (Figs. 1b-g).

135

H655Y governs the endosomal entry pathway of BA.1.1 – differential effects of E64d and
Camostat

Previous studies have shown that SARS-CoV-2 entry in HEK293T-ACE2 cells is predominantly endosomal whereas in Calu-3 cells entry is primarily through the plasma membrane (Peacock *et al.*, 2021). We thus decided to use HEK293T-ACE2-TMPRSS2 cells, which allow entry through both endosomal and plasma membrane routs, to determine the impact

142 of these BA.1.1 mutants on entry in the presence of the endosomal Cat L/B inhibitor E64d or the 143 TMPRSS2 inhibitor Camostat. While BA.1.1 was more sensitive to treatment by E64d but less 144 sensitive to treatment by Camostat compared to D614G, BA.1.1-Y655H was less sensitive to 145 E64d than BA.1.1, with a half maximal inhibitory concentration (IC₅₀) of > 25 μ M versus an IC₅₀ of 0.4 µM for the parental BA.1.1 (Figs. 2a and 2g). Additionally, BA.1.1-Y655H was more sensitive 146 147 to Camostat than BA.1.1, with an IC₅₀ of 10.3 μ M versus IC₅₀ >150 μ M for BA.1.1 (Figs. 2b and 148 2g). Convincingly, the forward mutant D614G-H655Y was more sensitive to E64d, with an IC₅₀ of 149 0.8 µM versus 23.5 µM for the parental D614G (Figs. 2c and 2g), but less sensitive to Camostat, 150 with an IC₅₀ of 91.3 µM versus 11.6 µM for the parental D614G (Figs. 2d and 2g). Overall, we 151 discovered that the BA.1.1 reversion mutant Y655H had a more than 14.6-fold decreased IC_{50} for 152 Camostat and an over 62.5-fold increased IC_{50} for E64d compared to the parental BA.1.1 (Fig. 153 **2g**). Further, the forward mutant H655Y has a 7.9-fold increased IC_{50} for Camostat and a 29.4-154 fold decreased IC₅₀ for E64d relative to the parental D614G (**Fig. 2g**). Of note, the T547K mutation 155 of BA.1.1 did not seem to have a dramatic impact on the sensitivity to these drug treatments (Figs. 156 **2a-d**, and **2g**).

157 To confirm the above pseudotype lentivirus results in an authentic SARS-CoV-2 system, we engineered the complete BA.1 full length (FL) spike (Pitts et al., 2022) into the infectious cDNA 158 159 clone of USA-WA1/2020 with mNeonGreen (Viana et al.) reporter (Xie et al., 2020) to obtain BA.1-160 FL mNG SARS-CoV-2 and then generated the individual reversion mutations of spike K547T or 161 Y655H in this background. Using these infectious viruses, we determined the impact of these two 162 mutations on BA.1 entry into Vero-ACE2-TMPRSS2 cells using the inhibitors E64d or Camostat. 163 The results showed that the parental BA.1-FL mNG SARS-CoV-2 was the most sensitive to E64d 164 with an IC₅₀ of 19.9 µM among the three viruses, followed by BA.1-FLmNG-K547T and then BA.1-165 FL mNG-Y655H, although these variants were generally much less sensitive to E64d compared 166 to that in 293T-ACE2 cells, with no exact IC_{50} value calculated for the two mutants (**Figs. 2e**, **2g**) 167 and S1a). In contrast, compared to the parental BA.1-FL mNG which was resistant to Camostat 168 treatment with an IC₅₀ of more than 150 µM, BA.1-FL mNG-K547T was sensitive to Camostat with 169 an IC₅₀ of 19.1 µM, a more than 7.9-fold reduction in IC₅₀ relative to BA.1-FL mNG; BA.1-FL mNG-170 Y655H was more sensitive to Camostat, with an IC₅₀ of 3.7 μ M, approximately > 40.5-fold 171 decreased IC₅₀ relative to BA.1.1 FL mNG (Figs. 2f, 2g and S1b). These results together 172 indicated T547K and H655Y mutations, especially the latter, greatly contribute to the altered entry 173 preference of BA.1 in target cells. Overall, the results of pseudotyped as well as authentic viruses 174 highlight the essential of role of H655Y mutation in dictating the Omicron BA.1 subvariant S-175 mediated endosomal entry compared to the ancestral D614G, which enters target cells 176 predominantly through the plasma membrane.

177

178 H655Y critically controls the low fusogenicity of BA.1.1 Spike

179 To investigate the underlying mechanism of the T547K and H655Y mutations in modulating 180 BA.1.1 entry preference, we examined the role of these two mutants along with N679K, P681H 181 and parental BA.1.1 in S expression and S-mediated membrane fusion. In parallel, the impacts 182 of the corresponding forward mutants were also investigated. Flow cytometric analysis of the S 183 surface expression in HEK293T cells used to produce pseudotyped lentivirus showed that all 184 these reversion mutants had approximately comparable levels of expression to each other and 185 the parental BA.1.1, except for the reversion mutant K547T, which had modestly reduced surface 186 expression (Figs. 3a-b), while all the forward mutants had similar levels of expression to D614G 187 (Fig. S2a-b). We then conducted syncytia formation assays in HEK293T-ACE2 cells transfected 188 to express GFP and the individual S constructs and observed that K547T and Y655H substantially 189 promoted the S-mediated cell-cell fusion, whereas K679N and H681P had no effect (Figs. 3c-d). 190 Surprisingly, while forward mutations H655Y and T547K slightly reduced the D614G S-induced 191 syncytia, two other mutations N679K and P681H enhanced D614G S-mediated fusion (Figs. S2c-192 d), similar to some previous reports (Rajah et al., 2021).

193

194 Reversion of H655Y to Y655H results in increased BA.1.1 S1 shedding

195 The efficiency of SARS-CoV-2 S cleavage by furin is known to be associated with 196 membrane fusogenicity (Johnson et al., 2021; Saito et al., 2022). We next examined how these 197 mutations might influence BA.1.1 S processing by analyzing the ratio of S1/S and S2/S in viral 198 producer cells and purified viral particles. In cell lysates, while K547T exhibited a slightly 199 increased or comparable ratio of S1/S and S2/S, H681P exhibited a decreased S1/S ratio but not 200 S2/S ratio, Y655H and K679N showed a decreased ratio of both S1/S and S2/S (Figs. 3e-g). 201 However, none of the four forward mutants showed obvious change in S1/S1 or S2/S ratios in the 202 cell lysates, except for N679K which exhibited a modestly increased S2/S ratio (Figs. S3a-c), 203 suggesting that these four mutations do not appear to significantly modulate BA.1.1 furin cleavage 204 in viral producer cells. Interestingly, we found that all four reversion mutants, most notably Y655H, 205 showed a decreased level of S1 and S2 compared to the parental BA.1.1 in viral particles after 206 being normalized by p24 (Figs. 3h-i). Additionally, the corresponding forward mutations T547K 207 and H655Y, especially the latter, substantially increased the S1/p24 and S2/p24 ratios in viral 208 particles relative to D614G (Figs. S3d-f). The drastically decreased level of S1 for Y655H in viral 209 particles corresponded to its significantly reduced infectivity in HEK293T-ACE2 and HEK293T-210 ACE2-TMPRSS2 cells, potentially due to premature inactivation by high level expression of ACE2 211 in these cells, despite apparently increased infectivity in Calu-3 cells (Figs. 1b-d). These results, 212 along with the increased fusogenicity of Y655H, suggest that the H655Y mutation in BA.1.1 213 critically governs its low fusion activity and differential entry between HEK293T-ACE2 and Calu-214 3 cells.

The comparable or modestly increased efficiency of furin cleavage in viral producer cells of K547T and Y655H reversion mutants, in contrast to their decreased levels of S1 in the virions, especially Y655H, were indeed surprising, especially given their significantly increased cell-cell fusion activity observed in HEK293T-ACE2 cells. One possibility is that the S1 subunit of these two reversion mutants, especially Y655H, was shed into culture media during virus production.

Indeed, we found that, compared to the parental BA.1.1, K547T and Y655H exhibited increased levels of S1 shedding into culture media in the presence of treatment by soluble ACE2 (**Figs. 3k and I**). Of note, S1 shedding of two other reversion mutants, K679N and H681P, was decreased compared to the parental BA.1.1, which appeared to correlate with their relatively low furin cleavage (**Figs. 4k and I**). Altogether, these results suggest that the T547K and H655Y mutations in BA.1.1, especially the latter, stabilize the spike conformation, contributing to decreased fusogenicity and entry in Calu-3 cells.

227

228 H655Y dictates the endosomal entry and low fusogenicity of other Omicron subvariants

229 As in BA.1.1, all previously or currently circulating Omicron subvariants contain the H655Y 230 substitution, but not T547K (Fig. S4). We therefore predicted that the H655Y mutation also 231 governs the entry preference and low fusogenicity of other variants. To this end, we introduced 232 the H655Y reversion mutation into these Omicron subvariants, i.e., BA.1, BA.2, BA.2.12.1, BA.4/5 233 and BA.2.75, and examined their impact on entry of these subvariants in HEK293T-ACE2 and 234 Calu-3 cells using the same HIV lentiviral pseudotyping system. We observed that the reversion 235 mutation Y655H significantly reduced the entry efficiency of all these Omicron subvariants in 236 HEK293T-ACE2 cells (Fig. 4a), but substantially promoted their entry in Calu-3 cells, although 237 the increase in Calu-3 cells was generally modest or not seen in some cases (Fig. 4b). We also 238 examined the influence of the reversion mutation Y655H on the fusogenicity of these Omicron 239 subvariants using the syncytia formation assay described above. Again, we found that similar to 240 BA.1.1, Y655H also significantly promoted the S-mediated syncytia formation of BA.1, BA.2, 241 BA.2.12.1, BA.4/5, and BA.2.75 (Figs. 4c-d).

To provide molecular insight into how T547K and H655Y might dictate the low fusogenicity and endosomal entry of the Omicron subvariants, we performed molecular modeling of Omicron BA.1.1 spike protein. Indeed, we found that the T547K mutation could establish a salt-bridge interaction with the residue D389 located on the base of the receptor binding domain (RBD), as

well as an inter-protomer hydrogen bond with the residue S982 on S2 domain, thus stabilizing its closed conformation and prevent S1 shedding (**Fig. 4e**). The mutation H655Y located in the proximity to the furin cleavage site in S could reduce local structural flexibility by forming hydrophobic interactions with residues F643, I670 and A694, which may interfere with or decrease the accessibility of furin to the cleavage site (**Fig. 4f**).

251

252 Discussion

253 Omicron exhibits exceptional immune evasion (Garcia-Beltran et al., 2022; Kuhlmann et 254 al., 2022; Planas et al., 2022; Pulliam et al., 2022; Viana et al., 2022) because of the presence of 255 large numbers of mutations in the S protein. We and others have reported that Omicron also 256 exhibits a distinct entry preference, substantially impaired furin cleavage, as well as decreased 257 cell-cell fusion (Meng et al., 2022; Qu et al., 2022b; Zeng et al., 2021). However, the molecular 258 mechanisms of these distinct features of the Omicron subvariants remain elusive. In this study, 259 we interrogated key mutations that govern the Omicron S-mediated low fusogenicity and 260 endosomal entry. We determined H655Y, and to lesser extent T547K, as the key mutation on the 261 S protein of Omicron that critically governs its preferential endosomal entry route and impaired 262 fusion activity, including for the recently emerged BA.4/5, BA.2.12.1 and BA.2.75 subvariants. 263 Moreover, through molecular modelling, we provide evidence that these mutations likely stabilize 264 the S trimer conformation by forming new molecular interactions. Together, these results provide 265 insights for understanding the altered cellular tropism and pathogenicity for Omicron.

The most important finding of this study is that the altered entry route preference of Omicron is largely determined by the key H655Y mutations. It is well established that SARS-CoV-2 is capable of utilizing either endosomal entry mediated by Cat L/B or plasma membrane entry mediated by TMPRSS2 (Bestle *et al.*, 2020; Hoffmann *et al.*, 2020; Peacock *et al.*, 2021). However, SARS-CoV-2 entry in primary lung epithelial cells and lung-derived cell lines such as Calu-3 cell is largely TMPRSS2 dependent (Peacock *et al.*, 2021), likely occurring on the plasma 272 membrane. Following its emergence, the Omicron variant BA.1 has been shown to have a distinct 273 entry profile, utilizing predominantly the endosomal entry pathway (Pia and Rowland-Jones, 2022), 274 exhibiting poor replication in lower airway derived primary cells and Calu-3 cells (Gupta, 2022). 275 as well as displaying reduced disease severity (Halfmann et al., 2022). We found that the H655Y 276 mutation governs BA.1.1 entry through endosomes, as suggested by the significant increase in 277 viral infectivity observed in HEK293T-ACE2 cells but substantial reduction in viral infectivity in 278 Calu-3 cells, and by the increased sensitivity of H655Y bearing variants to E64d, yet with 279 decreased sensitivity to Camostat, which are also supported by other recent studies (Hu et al., 280 2022; Yamamoto et al., 2022). However, the impact of H655Y on in vivo virus tropism and 281 pathogenicity remains to be investigated. If the altered entry route preference introduced by the 282 H655Y mutation is responsible for the enhanced nasopharynx tropism and reduced pathogenicity 283 of the Omicron subvariants, any reversion of the H655Y mutation in future variants would be of 284 great concern, as such a variant may exhibit enhanced pathogenicity. Careful monitoring this 285 reversion mutation in the pandemic is warranted.

286 Membrane fusion is critical for entry of all enveloped viruses. We found that reversion 287 mutations K547T and Y655H significantly promoted BA.1.1 S-mediated cell-cell fusion whereas 288 forward mutations T547K and H655Y slightly impaired the D614G S-mediated cell-cell fusion, 289 indicating that these two residues critically determine the low fusogenicity of BA.1.1. Quite 290 unexpectedly, we found no evidence that T547K and H655Y affect S processing of BA.1.1 in cell 291 lysates. Rather, reversion mutations K547T and Y655H strongly promote S1 shedding in the 292 presence of sACE2, indicating that T547K and H655Y mutations, especially the latter, critically 293 stabilize the BA.1.1 S conformation. This result is correlated with our structural modelling that 294 T547K appears to stabilize the close conformation of S protein, which is also supported by a 295 recent study reporting an extra hydrogen bond between the tyrosine residue at position 655 in S1 296 and the threonine residue at position 696 in S2 of BA.1 (Yamamoto et al., 2022). Further structural 297 analyses, including comparisons between K547T/Y655H reversion mutants and the parental

BA.1.1 or other Omicron subvariants by cryogenic electron microscopy (cryo-EM) or crystallography, are needed to further elucidate the role of T547K and/or H655Y in Omicron subvariant S conformation.

301 It is important to note that H655Y mutation has been found to be associated with SARS-302 CoV-2 infection in index cats and minks (BraunID et al., 2021; Escalera et al., 2022). In addition, 303 the H655Y mutation appears to have arisen independently multiple times in human population, 304 and is a lineage-defining mutation for the Gamma (P.1) SARS-CoV-2 variant in addition to the 305 Omicron subvariants (Escalera et al., 2022). Importantly, H655Y is present in all predominant 306 Omicron sublineages, including BA.1.1, BA.1, BA.2, BA.2.12.1 and more recent BA.4/5 and 307 BA.2.75, indicating that H655Y likely improves fitness and the ability to adapt to new hosts, 308 including humans, cats, minks, and others. This is supported by a recent report demonstrating an 309 enhancement of virus infectivity in mice for H655Y-containing viruses (Zhu et al., 2022).

Our findings in this work, along with other recent reports, together suggest that the occurrence of mutations at position 655 in S protein of current and future SARS-CoV-2 variants needs to be closely monitored. Additionally, *in vivo* examinations of the impact of the H655Y mutation on virus tropism and pathogenicity are critical and need to be investigated, as any reversion of the H655Y mutation could generate new concern for the course of the COVID-19 pandemic as novel Omicron subvariants continue to emerge.

316

317 Acknowledgements

We thank the NIH AIDS Reagent Program and BEI Resources for supplying important reagents that made this work possible. S.-L.L. was supported by a fund provided by an anonymous private donor to OSU. J.P.E. was supported by Glenn Barber Fellowship from the Ohio State University College of Veterinary Medicine. K.X. was supported by the Ohio State University Comprehensive Cancer Center and a Path to K Grant through the Ohio State University Center for Clinical & Translational Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of the university, or the Center for Clinical & Translational
Science. P.-Y.S. was supported by NIH grants HHSN272201600013C and U01AI151801, and
awards from the Sealy & Smith Foundation, the Kleberg Foundation, the John S. Dunn
Foundation, the Amon G. Carter Foundation, the Summerfield Robert Foundation, and Edith and
Robert Zinn.

329

330 Author Contributions

- 331 S.-L.L. conceived and directed the project. P.Q. performed majority of the described experiments,
- and J.P.E. performed experiments related to infectious viruses. C.K. made the infectious Omicron
- 333 BA.1 variants. C.Z. assisted in experiments. P.Q., J.P.E., and S.-L.L. wrote the paper. K.X.
- performed homology modeling. C.Z., Y.-M.Z., K.X., P.-Y.S., and X.X. provided insightful
 discussion and revision of the manuscript.
- 336

337 Competing Interest Declaration

- 338 The authors have no competing interests to disclose
- 339

340 **Figure legends**:

341 Figure 1: H655Y governs differential entry of Omicron BA.1.1 into distinct target cells. (a) 342 Schematic representations of BA.1.1 and D614G Spike glycoprotein are presented. The N-343 terminal domain (NTD), the receptor binding domain (RBD), the fusion peptide (FP) and the 344 transmembrane (TM) region are indicated. Only the mutations at the C-terminus of S1 and those 345 near the S1/S2 junction in BA.1.1 S relative to SARS-CoV-2 D614G S are shown (Top, BA.1.1) 346 (MIcochova et al.); also displayed are these four amino acid mutations of BA.1.1 S replaced with 347 the corresponding amino acid in the D614G S (Middle, BA.1.1 reversion mutations), and these 348 four residues in D614G S substituted with the corresponding amino acid in BA.1.1 S (**Bottom**, 349 D614G forward mutations). (b-d) The relative infectivity of pseudotyped viruses encoding BA.1.1

350 S with single mutated amino acids replaced with the corresponding amino acid in the D614G S in 351 HEK293T-ACE2 cells (n=6) (b), HEK293T-ACE2-TMPRSS2 cells (n=6) (c), and Calu-3 cells (n=4) (d). The luciferase activity of parental BA.1.1 was set as 1.0 for comparison. (Deng et al.) The 352 353 relative infectivity of pseudotyped viruses encoding D614G S with single amino acids substituted 354 with the corresponding amino acid in the BA.1.1 S in HEK293T-ACE2 cells (n=6) (e). HEK293T-355 ACE2-TMPRSS2 cells (n=6) (f), and Calu-3 cells (n=4) (g). The luciferase activity of parental 356 D614G was set as 1.0. In call cases, bars represent means +/- standard error, and significance 357 was determined by one-way ANOVA with Bonferroni's multiple testing correction. P-values are 358 represented as ns indicates $p \ge 0.05$, *p < 0.05, ***p < 0.001, ****p < 0.0001.

359

360 Figure 2: H655Y dictates BA.1.1 entry through the endosomal pathway. HEK293T-ACE2-361 TMPRSS2 cells were pretreated with E64d (a and c) or Camostat (b and d), and then transduced 362 with the indicated pseudotyped viruses in the presence of varying concentrations of the inhibitors. 363 The relative infection was calculated by setting the luciferase activity of each virus at the 0 μ M of 364 the inhibitors as 100%, and the half maximal inhibitory concentration (IC_{50}) values were 365 determined by non-linear regression with least squares fit. Vero-ACE2-TMPRSS2 cells were 366 pretreated with E64d (e) or Camostat (f), followed by infection with parental BA.1 FL mNG or its 367 mutants. The infection ratio was determined by flow cytometry, and relative infection was 368 calculated by setting the infection percentage of each virus in the absence of the drugs as 100%. 369 (g) IC_{50} values of each virus in the presence of the individual drugs are shown. Additionally, the 370 IC₅₀ fold change relative to parental BA.1 (or BA.1 FL mNG) or D614G are displayed.

371

Figure 3: H655Y critically controls the low fusogenicity of BA.1.1 S. (a) The S expression on the cell surface of HEK293T cell used to produce pseudotyped lentivirus was determined by staining cells with anti-SARS-CoV-2 S1 (T62) antibodies. Representative flow cytometric

375 histograms of the S1 signal are shown. (b) Mean fluorescence intensity of S1 signal was 376 calculated and shown, n=4. (c-d) Syncytia formation was assayed in HEK293T-ACE2 cells 377 transfected to express S construct of interest and GFP. The average area of fused cells from one 378 of five independent experiments (c) and representative syncytia images (d) are shown. Scale 379 bars represent 150 µm. (e) Producer cell lysates were probed for S1 subunit, S2 subunit, p24, 380 and GAPDH, respectively. S signals were quantified using NIH ImageJ and relative efficiency of 381 S cleavage was calculated by setting the ratio of S1/S or S2/S of BA.1.1 to 1.00. Representative 382 blots are shown. The relative ratios of S1/S (f) and S2/S (g) from three independent experiments 383 are shown. (h) The pseudovirions were purified and blotted for S1, S2, and p24, and S1 or S2 384 signals in virions were quantified and normalized to p24. The relative S1/p24 or S2/p24 was 385 calculated by setting the ratio of BA.1.1 to 1.00. The relative S1/p24 (i) and the relative S2/p24 (j) 386 ratios from three independent experiments are shown. (k-I) Reversion of H655Y to Y655H 387 enhances BA.1.1 S1 shedding. HEK293T cells transfected with indicated S constructs were 388 treated with soluble ACE2-Fc (sACE2), followed by immunoprecipitation (IP) of S1 in the culture 389 media by anti-FLAG beads. S in the IP products (k) were probed for SARS-CoV-2 S1, with 390 GAPDH as a loading control. Relative S1 in the IP products is shown (I), calculated by setting the 391 S1 signals of BA.1.1 to 1.0. The error bars in (**b**, **c**, **f**, **g**, **i**, **j** and **l**) are means +/- standard error; 392 ns indicates $p \ge 0.05$, *p < 0.05, **p < 0.01, ****p < 0.0001.

393

Figure 4: H655Y dictates the endosome entry preference and the low fusogenicity of all major Omicron subvariants. (a) Infectivity of pseudotyped viruses in HEK293T-ACE2 cells is shown, n=3. (b) Infectivity of pseudotyped lentivirus in CaLu-3 cells is also displayed, n=3. (c-d) Syncytia formation assays in HEK293T-ACE2 cells were performed as described in Fig. 3. Representative syncytia images (c) and the average area of fused cells (d) are shown, n=3. Scale bars represent 150 µm. (e) Molecular modelling. The T547K mutation introduces a salt-bridge interaction with the D389 located on the base of the RBD, and a hydrogen bond with residue S982

- 401 in the S2 domain. (f) BA.1.1 H655Y mutation reduces local conformational flexibility by creating
- 402 hydrophobic contacts with residues F643, A694 and I670, which may interfere with the furin
- 403 accessibility to the cleavage site nearby. Bars in (a), (b) and (d) represent means +/- standard
- 404 error, and significance is determined by two-tailed Student's t test with Welch's correction. P-
- 405 values are represented as ns for $p \ge 0.05$, *p<0.05, **p < 0.01, ***p < 0.001.
- 406

407 Materials and Methods

408 Cell Lines and Maintenance

409 HEK293T (ATCC CRL-11268, research resource identifier [RRID]; CVCL 1926), HEK293T-410 ACE2 (BEI NR-52511, RRID: CVCL A7UK) and Vero E6 expressing high endogenous ACE2 411 (Vero-ACE2) (BEI NR-53726, RRID:CVCL A7UJ) supplemented with 1% penicillin/streptomycin 412 (MilliporeSigma, P4333) and 10% (v/v) fetal bovine serum (FBS) (Thermo Fisher Scientific, 413 26140-079). Calu-3, a gift of Estelle Cormet-Boyaka at The Ohio State University, were grown in 414 Eagle's Minimum Essential medium (EMEM) (ATCC, 30-2003), supplemented with 1% 415 penicillin/streptomycin and 10% (vol/vol) FBS. HEK293T-ACE2 cells or Vero-ACE2 cells stably 416 expressing TMPRSS2 were generated by transduction of pLX304 vectors expressing TMPRSS2 417 (a gift from Siyuan Ding at the Washington University in St. Louis), and selection by Blasticidine 418 S hydrochloride (MilliporeSigma, 15205) (10 µg/ml for HEK293T-ACE2 cells and 7.5 µg/ml for 419 Vero-ACE2 cells) for 7-14 days. All cell lines in this study were maintained at 37°C in the presence 420 of 5% CO₂.

421

422 Plasmids and constructs

Constructs harboring different mutations were generated by long PCR mutagenesis based on
pcDNA3.1-SARS-CoV-2-Flag-S-Flag-D614G, pcDNA3.1-SARS-CoV-2-Flag-S-Flag-BA.1.1,
pcDNA3.1-SARS-CoV-2-Flag-S-Flag-BA.1, pcDNA3.1-SARS-CoV-2-Flag-S-Flag-BA.2,
pcDNA3.1-SARS-CoV-2-Flag-S-Flag-BA.2.12.1, pcDNA3.1-SARS-CoV-2-Flag-S-Flag-BA.4/5 or
pcDNA3.1-SARS-CoV-2-Flag-S-Flag-BA.2.75. HIV-1 NL4.3-inGluc was from Marc Johnson at
the University of Missouri (Columbia, Missouri, USA).

429

430 Generation of BA.1 FL-mNG and related mutant viruses

431 Infectious cDNA clone of USA-WA1/2020 and Omicron (BA.1) SARS-CoV-2 were generated
432 using PCR-based mutagenesis as previously described (Pitts et al., 2022; Xie et al., 2020). To

433 construct spike mutant K547T or Y655H mutant viruses, nucleotide substitutions were introduced 434 through standard mutagenesis approach into a subclone pcc1-CoV-2-BA.1-F567 containing the 435 spike gene of SARS-CoV-2 BA.1. The full-length infectious cDNA clone of SARS-CoV-2 was 436 assembled by in vitro ligation of three contiguous cDNA fragments following the previously 437 described protocol (Liu et al., 2022b; Xie et al., 2020). In vitro transcription was performed to 438 synthesize full length viral genomic RNA. The RNA transcripts were electroporated in Vero E6 439 cells expressing TMPRSS2 (purchased from SEKISUI XenoTech, LLC) to recover the mutant 440 viruses. Viruses were rescued post 2-4 days after electroporation and served as P0 stock. P0 441 stock was further passaged once on Vero E6 cells expressing TMPRSS2 to produce P1 stock. 442 Spike gene was sequenced from all P1 stock viruses to validate the mutations. P1 stock was 443 titrated by plaque assay on Vero E6 cells expressing TMPRSS2 and used for subsequent 444 experiments. All virus preparation were carried out at biosafety level 3 (BSL-3) facility at the 445 University of Texas Medical Branch at Galveston.

446

447 Virus production and infection

HEK293T cells were transfected with 0.7 µg of different Spike plasmids along with 1.4 µg of HIV1-NL4.3-inGluc at a 1:2 ratio using polyelthylenimine transfection (Cui et al.). Then, 48-72 hrs
post-transfection, the culture supernatants were harvested. After removing the cell debris by
spinning down at 3000 g for 10 minutes, the viruses were aliquoted and stored at -80°C.

Pseudovirions were transduced into various cell lines; 6 hrs post-transduction, the media were
changed. Gaussia luciferase activity was measured at 48-96 hrs after infection to determine the
relative infectivity or entry efficiency of the indicated viruses.

455

For the inhibition assay using pseudotyped viruses, HEK293T-ACE2-TMPRSS2 cells were pretreated with indicated concentrations of EST/E-64D (E64d) (Sigma, 330005) or camostat mesylate (Camostat) (Sigma, SML0057) for 1 h, followed by transduction with pseudovirions of

interest in the presence of the same concentrations of the drugs. After changing the media 6 hpi,the luciferase activity was measured at 48 and 72 hpi, respectively.

461

For the inhibition assay using infectious viruses, Vero-ACE2-TMPRSS2 cells were pretreated with indicated concentrations of EST/E-64D (E64d) (Sigma, 330005) or camostat mesylate (Camostat) (Sigma, SML0057) for 1 h, followed by infection with infectious viruses in the presence of the same concentrations of the inhibitors for 24 hrs. Subsequently, the cells were fixed with 3.7% formaldehyde for 1 h and analyzed by a Life Technologies Attune NxT flow cytometer.

467

468 Flow cytometry

HEK293T cells used for the production of virions were washed with 1×PBS once, detached with 5 mM EDTA in PBS, washed with washing buffer (1×PBS containing 2% FBS) twice, following by fixing with 3.7% formaldehyde for 10 min. Then the cells were incubated with anti-SARS-CoV-2 Spike antibodies (T62) for 1 hr on ice. After three washes with cold washing buffer, the cells were incubated with FITC-conjugated anti-rabbit IgG antibodies for 1 hr. Subsequently, the cells were washed twice and analyzed by a Life Technologies Attune NxT flow cytometer.

475

476 Syncytia formation assay

HEK293T-ACE2 cells were cotransfected with GFP constructs and parental D614G S, Omicron S, or their related mutants, followed by imaging the syncytia formation under a Leica DMi8 fluorescence microscope after 24 h of transfection. The cell-cell fusion efficiency was analyzed by measuring areas of the fused cells from three representative images using the "Leica Application Suit X" software. Scale bars represent 150 µm.

482

483 Western blotting

484 Western blotting was conducted as previously described (Zeng et al., 2020). Briefly, cells were 485 collected and lysed in 200 ul of RIPA buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 1 mM EDTA, 486 Nonidet P-40, 0.1% SDS) in the presence of protease inhibitor cocktail (MilliporeSigma, P8340). 487 followed by clarification at 13200 rpm for 10 minutes, and boiling for 10 minutes at 100°C with 1x 488 SDS loading buffer. To determine the Spike content in virion particles, pseudovirus supernatant 489 was collected, filtered and purified by ultracentrifugation through a 20% sucrose cushion. The 490 purified virions were dissolved in 1x SDS loading buffer. Subsequently, the samples were 491 separated by 10% SDS-PAGE gels, transferred to PVDF membranes and immunoblotted with 492 anti-S1 (Sino Biological, 40150-T62), anti-S2 (Sino Biological, 40590-T62), anit-GAPDH (Santa 493 Cruz, sc-47724), and anti-p24 (anti-p24 (NIH ARP-1513) antibodies, followed by immunoblotting 494 with anti-mouse-IgG-Peroxidase (Sigma, A5278) or anti-rabbit-IgG-HRP (Sigma, A9169) 495 antibodies.

496

497 Soluble ACE2-induced S1 shedding assay

HEK293T cells were transfected with the indicated Omicron Spike constructs and were treated or untreated with soluble ACE2-Fc (sACE2-Fc) at 37°C for 4 hrs. Subsequently, the cell culture media and cells were collected, and anti-FLAG beads (Sigma, F2426) were used to precipitate S1 subunit in the media. Following immune-precipitation, the samples were separated on 10% SDS-PAGE gel, and probed with anti-S1 (Sino Biological, 40150-T62), anti-S2 (Sino Biological, 40590-T62) and anti-GAPDH (Santa Cruz, sc-47724). Anti-mouse-IgG-Peroxidase (Sigma, A5278) and anti-rabbit-IgG-HRP (Sigma, A9169) were used as secondary antibodies.

505

506 Structural modeling and analysis

507 Homology modeling of Omicron spike protein was performed on SWISS-MODEL server with cryo-508 EM structure of SARS-CoV2 G614 strain spike (PDB 7KRR) as template. The resulting homo-509 trimer spike structure has one RBD in up conformation and the other two RBD in down

521	(Figs. 4a, 4b, and 4d).
520	and Figs. S4e-f), and an unpaired, two-tailed Student's t test with Welch's correction was used
519	for multiple comparison (Figs. 1b-g, Figs. 3b, 3c, 3f, 3g,3i, 3j and 3l, Figs. S3b-c, Figs. S4b-c,
518	(ANOVA) with Bonferroni's post-tests to compute statistical significance between multiple groups
517	Diego, CA) and are referenced in the figure legends and include one-way Analysis of Variance
516	specifically indicated. Statistical significance analyses were performed in GraphPad Prism 9 (San
515	All experiments were conducted in at least three independent replications except for those
514	Statistical analysis
513	
512	contacts of Omicron mutants were examined and illustrated with the programs PyMOL.
511	Coot. Inter-protomer interaction analysis was performed with PDBePISA server. Molecular
510	conformation. Residue examination and renumbering were carried out manually with program

522

523 References:

- 524 Bestle, D., Heindl, M.R., Limburg, H., Van Lam van, T., Pilgram, O., Moulton, H., Stein, D.A., 525 Hardes, K., Eickmann, M., Dolnik, O., et al. (2020). TMPRSS2 and furin are both essential for 526 proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 3. 527 10.26508/lsa.202000786.
- 528 BraunID, K.M., MorenoID, G.K., Halfmann, P.J., HodcroftID, E.B., BakerID, D.A., BoehmID, E.C.,
- 529 Weiler, A.M., HajID, A.K., HattaID, M., ChibaID, S., et al. (2021). Transmission of SARS-CoV-2
- in domestic cats imposes a narrow bottleneck. PLoS Pathog *17*. <u>https://doi.org/10.1371/journal</u>.
 ppat.1009373.
- 532 Cao, Y., Yisimayi, A., Jian, F., Song, W., Xiao, T., Wang, L., Du, S., Wang, J., Li, Q., Chen, X., et
 533 al. (2022). BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature 608,
 593-602. 10.1038/s41586-022-04980-y.
- 535 Carreno, J.M., Alshammary, H., Tcheou, J., Singh, G., Raskin, A.J., Kawabata, H., Sominsky, 536 L.A., Clark, J.J., Adelsberg, D.C., Bielak, D.A., et al. (2022). Activity of convalescent and vaccine 537 corrum against SABS CoV 2 Omigrap, Nature 602 682 688, 10 1028/o41586 022 04200 5
- serum against SARS-CoV-2 Omicron. Nature *602*, 682-688. 10.1038/s41586-022-04399-5.
 Cui, Z., Liu, P., Wang, N., Wang, L., Fan, K., Zhu, Q., Wang, K., Chen, R., Feng, R., Jia, Z., et al.
- (2022). Structural and functional characterizations of infectivity and immune evasion of SARS CoV-2 Omicron. Cell *185*, 860-871 e813. 10.1016/j.cell.2022.01.019.
- 541 Deng, X., Garcia-Knight, M.A., Khalid, M.M., Servellita, V., Wang, C., Morris, M.K., Sotomayor-542 González, A., Glasner, D.R., Reyes, K.R., Gliwa, A.S., et al. (2021). Transmission, infectivity, and 543 neutralization of a spike L452R SARS-CoV-2 variant. Cell *184*, 3426-3437.e3428.
- 544 10.1016/j.cell.2021.04.025.
 545 Diamond, M., Halfmann, P., Maemura, T., Iwatsuki-Horimoto, K., Iida, S., Kiso, M., Scheaffer, S.,
- 546 Darling, T., Joshi, A., Loeber, S., et al. (2021). The SARS-CoV-2 B.1.1.529 Omicron virus causes 547 attenuated infection and disease in mice and hamsters. Res Sq. 10.21203/rs.3.rs-1211792/v1.
- 548 Du, X., Tang, H., Gao, L., Wu, Z., Meng, F., Yan, R., Qiao, S., An, J., Wang, C., and Qin, F.X. 549 (2022). Omicron adopts a different strategy from Delta and other variants to adapt to host. Signal 550 Transduct Target Ther 7, 45. 10.1038/s41392-022-00903-5.
- 551 Escalera, A., Gonzalez-Reiche, A.S., Aslam, S., Mena, I., Laporte, M., Pearl, R.L., Fossati, A.,
- 552 Rathnasinghe, R., Alshammary, H., van de Guchte, A., et al. (2022). Mutations in SARS-CoV-2 553 variants of concern link to increased spike cleavage and virus transmission. Cell Host Microbe *30*,
- 554 373-387 e377. 10.1016/j.chom.2022.01.006.
- Evans, J.P., Zeng, C., Qu, P., Faraone, J., Zheng, Y.M., Carlin, C., Bednash, J.S., Zhou, T.,
 Lozanski, G., Mallampalli, R., et al. (2022). Neutralization of SARS-CoV-2 Omicron sub-lineages
 BA.1, BA.1.1, and BA.2. Cell Host Microbe. 10.1016/j.chom.2022.04.014.
- 558 Garcia-Beltran, W.F., St Denis, K.J., Hoelzemer, A., Lam, E.C., Nitido, A.D., Sheehan, M.L., 559 Berrios, C., Ofoman, O., Chang, C.C., Hauser, B.M., et al. (2022). mRNA-based COVID-19
- vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. Cell *185*,
 457-466 e454. 10.1016/j.cell.2021.12.033.
- 562 Gupta, R. (2022). SARS-CoV-2 Omicron spike mediated immune escape and tropism shift. Res 563 Sq. 10.21203/rs.3.rs-1191837/v1.
- Hachmann, N.P., Miller, J., Collier, A.Y., Ventura, J.D., Yu, J., Rowe, M., Bondzie, E.A., Powers,
- 565 O., Surve, N., Hall, K., and Barouch, D.H. (2022). Neutralization Escape by SARS-CoV-2 Omicron
- 566 Subvariants BA.2.12.1, BA.4, and BA.5. N Engl J Med 387, 86-88. 10.1056/NEJMc2206576.
- 567 Halfmann, P.J., lida, S., lwatsuki-Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S.M., Darling,
- 568 T.L., Joshi, A., Loeber, S., Singh, G., et al. (2022). SARS-CoV-2 Omicron virus causes attenuated
- 569 disease in mice and hamsters. Nature 603, 687-692. 10.1038/s41586-022-04441-6.
- 570 Hoffmann, M., Kleine-Weber, H., Schroeder, S., Kruger, N., Herrler, T., Erichsen, S., Schiergens,
- 571 T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 Cell Entry Depends on ACE2

- and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell *181*, 271-280 e278.
 10.1016/j.cell.2020.02.052.
- Hu, B., Chan, J.F., Liu, H., Liu, Y., Chai, Y., Shi, J., Shuai, H., Hou, Y., Huang, X., Yuen, T.T., et al. (2022). Spike mutations contributing to the altered entry preference of SARS-CoV-2 Omicron
- 576 BA.1 and BA.2. Emerg Microbes Infect, 1-31. 10.1080/22221751.2022.2117098.
- Johnson, B.A., Xie, X., Bailey, A.L., Kalveram, B., Lokugamage, K.G., Muruato, A., Zou, J., Zhang,
 X., Juelich, T., Smith, J.K., et al. (2021). Loss of furin cleavage site attenuates SARS-CoV-2
 pathogenesis. Nature *591*, 293-299. 10.1038/s41586-021-03237-4.
- 580 Kuhlmann, C., Mayer, C.K., Claassen, M., Maponga, T., Burgers, W.A., Keeton, R., Riou, C., 581 Sutherland, A.D., Suliman, T., Shaw, M.L., and Preiser, W. (2022). Breakthrough infections with 582 SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet 399, 625-626. 583 10.1016/S0140-6736(22)00090-3.
- Liu, L., Iketani, S., Guo, Y., Chan, J.F., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M.S., et al. (2022a). Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature *602*, 676-681. 10.1038/s41586-021-04388-0.
- Liu, Y., Liu, J., Johnson, B.A., Xia, H., Ku, Z., Schindewolf, C., Widen, S.G., An, Z., Weaver, S.C.,
 Menachery, V.D., et al. (2022b). Delta spike P681R mutation enhances SARS-CoV-2 fitness over
 Alpha variant. Cell Rep *39*, 110829. 10.1016/j.celrep.2022.110829.
- 590 Marc Stegger, Sofie Marie Edslev, Raphael Niklaus Sieber, Anna Cäcilia Ingham, Kim Lee Ng,
- Man-Hung Eric Tang, Soren Alexandersen, Jannik Fonager, Rebecca Legarth, Magdalena Utko,
 et al. (2022). Occurrence and significance of Omicron BA.1 infection followed by BA.2 reinfection.
 medRxiv. https://doi.org/10.1101/2022.02.19.22271112.
- McMahan, K., Giffin, V., Tostanoski, L.H., Chung, B., Siamatu, M., Suthar, M.S., Halfmann, P.,
 Kawaoka, Y., Piedra-Mora, C., Jain, N., et al. (2022). Reduced pathogenicity of the SARS-CoV-
- 596 2 omicron variant in hamsters. Med (N Y) 3, 262-268 e264. 10.1016/j.medj.2022.03.004.
- 597 Meng, B., Abdullahi, A., Ferreira, I., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., 598 Gerber, P.P., Fatihi, S., Rathore, S., et al. (2022). Altered TMPRSS2 usage by SARS-CoV-2 599 Omicron impacts infectivity and fusogenicity. Nature. 10.1038/s41586-022-04474-x.
- MIcochova, P., Kemp, S.A., Dhar, M.S., Papa, G., Meng, B., Ferreira, I., Datir, R., Collier, D.A.,
 Albecka, A., Singh, S., et al. (2021). SARS-CoV-2 B.1.617.2 Delta variant replication and immune
 evasion. Nature 599, 114-119. 10.1038/s41586-021-03944-y.
- 603 Mykytyn, A.Z., Breugem, T.I., Riesebosch, S., Schipper, D., van den Doel, P.B., Rottier, R.J.,
- Lamers, M.M., and Haagmans, B.L. (2021). SARS-CoV-2 entry into human airway organoids is serine protease-mediated and facilitated by the multibasic cleavage site. Elife *10*. 10.7554/eLife.64508.
- 607 Peacock, T.P., Goldhill, D.H., Zhou, J., Baillon, L., Frise, R., Swann, O.C., Kugathasan, R., Penn,
- R., Brown, J.C., Sanchez-David, R.Y., et al. (2021). The furin cleavage site in the SARS-CoV-2
- 609 spike protein is required for transmission in ferrets. Nature Microbiology 6, 899-+. 610 10.1038/s41564-021-00908-w.
- 611 Perez-Then, E., Lucas, C., Monteiro, V.S., Miric, M., Brache, V., Cochon, L., Vogels, C.B.F., Malik,
- A.A., De la Cruz, E., Jorge, A., et al. (2022). Neutralizing antibodies against the SARS-CoV-2
 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster
 vaccination. Nat Med 28, 481-485. 10.1038/s41591-022-01705-6.
- 615 Pia, L., and Rowland-Jones, S. (2022). Omicron entry route. Nat Rev Immunol 22, 144. 10.1038/s41577-022-00681-9.
- 617 Pitts, J., Li, J., Perry, J.K., Du Pont, V., Riola, N., Rodriguez, L., Lu, X., Kurhade, C., Xie, X.,
- 618 Camus, G., et al. (2022). Remdesivir and GS-441524 Retain Antiviral Activity against Delta,
- 619 Omicron, and Other Emergent SARS-CoV-2 Variants. Antimicrob Agents Chemother 66, 620 e0022222. 10.1128/aac.00222-22.

- Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland,
 W.H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022). Considerable escape of SARS-CoV-2
 Omicron to antibody neutralization. Nature *602*, 671-675. 10.1038/s41586-021-04389-z.
- Pulliam, J.R.C., van Schalkwyk, C., Govender, N., von Gottberg, A., Cohen, C., Groome, M.J.,
 Dushoff, J., Mlisana, K., and Moultrie, H. (2022). Increased risk of SARS-CoV-2 reinfection
- 626 associated with emergence of Omicron in South Africa. Science, eabn4947. 627 10.1126/science.abn4947.
- Qu, P., Faraone, J., Evans, J.P., Zou, X., Zheng, Y.M., Carlin, C., Bednash, J.S., Lozanski, G.,
 Mallampalli, R.K., Saif, L.J., et al. (2022a). Neutralization of the SARS-CoV-2 Omicron BA.4/5
 and BA.2.12.1 Subvariants. N Engl J Med. 10.1056/NEJMc2206725.
- Qu, P., Faraone, J.N., Evans, J.P., Zou, X., Zheng, Y.-M., Carlin, C., Bednash, J.S., Lozanski, G.,
 Mallampalli, R.K., Saif, L.J., et al. (2022b). Differential Evasion of Delta and Omicron Immunity
 and Enhanced Fusogenicity of SARS-CoV-2 Omicron BA.4/5 and BA.2.12.1 Subvariants. BioRxiv.
 https://doi.org/10.1101/2022.05.16.492158.
- Rajah, M.M., Hubert, M., Bishop, E., Saunders, N., Robinot, R., Grzelak, L., Planas, D., Dufloo,
- J., Gellenoncourt, S., Bongers, A., et al. (2021). SARS-CoV-2 Alpha, Beta, and Delta variants
 display enhanced Spike-mediated syncytia formation. EMBO J 40, e108944.
 10.15252/embj.2021108944.
- Saito, A., Irie, T., Suzuki, R., Maemura, T., Nasser, H., Uriu, K., Kosugi, Y., Shirakawa, K.,
 Sadamasu, K., Kimura, I., et al. (2022). Enhanced fusogenicity and pathogenicity of SARS-CoV2 Delta P681R mutation. Nature *602*, 300-306. 10.1038/s41586-021-04266-9.
- Viana, R., Moyo, S., Amoako, D.G., Tegally, H., Scheepers, C., Althaus, C.L., Anyaneji, U.J.,
 Bester, P.A., Boni, M.F., Chand, M., et al. (2022). Rapid epidemic expansion of the SARS-CoV2 Omicron variant in southern Africa. Nature. 10.1038/s41586-022-04411-y.
- Wang, Q., Guo, Y., Iketani, S., Nair, M.S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A.D., Chang,
 J.Y., et al. (2022). Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and
 BA.5. Nature *608*, 603-608. 10.1038/s41586-022-05053-w.
- Kia, H., Zou, J., Kurhade, C., Cai, H., Yang, Q., Cutler, M., Cooper, D., Muik, A., Jansen, K.U.,
 Xie, X., et al. (2022). Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against
 Omicron SARS-CoV-2. Cell Host Microbe *30*, 485-488 e483. 10.1016/j.chom.2022.02.015.
- Kie, X., Muruato, A., Lokugamage, K.G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf,
 C., Bopp, N.E., Aguilar, P.V., et al. (2020). An Infectious cDNA Clone of SARS-CoV-2. Cell Host
- 653 Microbe 27, 841-848 e843. 10.1016/j.chom.2020.04.004.
- 654 Yamamoto, M., Tomita, K., Hirayama, Y., Inoue, J.I., Kawaguchi, Y., and Gohda, J. (2022). SARS-655 CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry 656 pathway and reduction of cell surface entry pathways. BioRxiv. 657 https://doi.org/10.1101/2022.03.21.485084.
- Yu, J., Collier, A.Y., Rowe, M., Mardas, F., Ventura, J.D., Wan, H., Miller, J., Powers, O., Chung,
 B., Siamatu, M., et al. (2022). Neutralization of the SARS-CoV-2 Omicron BA.1 and BA.2 Variants.
 N Engl J Med 386, 1579-1580. 10.1056/NEJMc2201849.
- 661 Zeng, C., Evans, J.P., Pearson, R., Qu, P., Zheng, Y.M., Robinson, R.T., Hall-Stoodley, L., Yount,
- J., Pannu, S., Mallampalli, R.K., et al. (2020). Neutralizing antibody against SARS-CoV-2 spike in
 COVID-19 patients, health care workers, and convalescent plasma donors. JCI Insight 5.
 10.1172/jci.insight.143213.
- Zeng, C., Evans, J.P., Qu, P., Faraone, J., Zheng, Y.M., Carlin, C., Bednash, J.S., Zhou, T.,
 Lozanski, G., Mallampalli, R., et al. (2021). Neutralization and Stability of SARS-CoV-2 Omicron
- 667 Variant. bioRxiv. 10.1101/2021.12.16.472934.
- 668 Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu, Y., Li, B., Huang,
- 669 C.L., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat
- 670 origin. Nature 579, 270-273. 10.1038/s41586-020-2012-7.

- Zhu, Y., Zhou, W., Niu, Z., Sun, J., Zhang, Z., Li, Q., Zheng, Y., Wang, C., Gao, L., and Sun, Q.
 (2022). Long-range enhancement of N501Y-endowed mouse infectivity of SARS-CoV-2 by the
 non-RBD mutations of Ins215KLRS and H655Y. Biol Direct *17*, 14. 10.1186/s13062-022-00325x.
- 675
- 676
-
- 677

(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is mac available under aCC-BY-NC 4.0 International license.



(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is m available under aCC-BY-NC 4.0 International license.



*, NA, not assessed.



Figure 3

(which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is maximum available under a BY-NC 4.0 International license.

